文献速递乳腺癌放疗姑息放疗与转移瘤

放疗模式对炎性乳腺癌局部区域控制的影响

Impact of Radiation Therapy Modalities on Loco-regional Control in Inflammatory Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-04-15

这项回顾性多中心研究纳入2010至2017年治疗的241例局限性炎性乳腺癌患者,165例接受标准放疗、76例接受强化放疗。中位随访40个月,两组局部区域复发(P=.68)和远处复发(P=.29)累积发生率均无差异,严重毒性相似。作者认为强化放疗未带来局部区域或远处控制获益,需汇总前瞻性研究及Meta分析加以验证。

要点

  • 241例炎性乳腺癌中,标准放疗165例、强化放疗76例,强化组淋巴结受累显著更多。
  • 中位随访40个月,两组局部区域复发P=.68、远处复发P=.29,均无差异。
  • 5年局部区域与远处复发风险:标准放疗12.1%与29.4%,强化放疗10.4%与21.4%。

核心结论

  • 与其他重要系列相反,这项大型回顾性多中心研究未显示强化放疗带来局部区域或远处控制获益。
  • 作者认为需汇总前瞻性研究及Meta分析来验证强化放疗这一做法。

研究设计与样本

  • 回顾性多中心研究,纳入2010至2017年治疗的241例局限性炎性乳腺癌患者。
  • 标准术后放疗为每日分次、总剂量50 Gy等效、不加量或不加填充物;强化放疗指使用加量或填充物。
  • 165例接受标准放疗,76例接受强化放疗;强化组淋巴结受累显著更多。
  • 采用竞争风险法展示局部区域和远处复发的累积发生率曲线。

主要发现

  • 放疗后中位随访40个月,标准与强化放疗的局部区域复发(P=.68)和远处复发(P=.29)累积发生率均无差异。
  • 5年局部区域复发风险:标准放疗12.1%(95% CI,7.5;17.7)vs 强化放疗10.4%(95% CI,4.4;19.3)。
  • 5年远处复发风险:标准放疗29.4%(95% CI,21.8;37.3)vs 强化放疗21.4%(95% CI,12.6;31.9)。
  • 多因素分析中,三阴性亚型和未达完全病理缓解与更高的局部区域复发风险相关。
  • 未达完全病理缓解的患者(n=172,71.7%)中,两组局部区域复发(P=.80)和远处复发(P=.39)均无显著差异;两组严重毒性发生率相似。

关键数值与推荐

  • 标准术后放疗:每日分次至总剂量50 Gy等效,不加量、不使用填充物。
  • 强化放疗:使用加量或填充物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In inflammatory breast cancer, radiation therapy intensification is considered a standard of care by some teams, although the level of evidence remains low. We sought to analyze the impact of radiation therapy modalities on the risk of loco-regional and distant relapse. METHODS AND MATERIALS: This retrospective multicenter study included patients with localized inflammatory breast cancer treated between 2010 and 2017. Standard postmastectomy radiation therapy consisted of daily fractions to a total dose of 50 Gy equivalent without a boost or bolus, while intensified radiation therapy referred to the use of a boost or bolus. The cumulative incidence curves of locoregional and distant recurrence were displayed using the competing risk method. RESULTS: Of the 241 included patients, 165 were treated with standard and 76 with intensified radiation therapy. There was significantly more nodal involvement in the intensified group. With a median follow-up of 40 months postradiation therapy, there was no difference between standard versus intensified radiation therapy regarding the cumulative incidence of locoregional (P = .68) or distant recurrence (P = .29). At 5 years, the risks of locoregional and distant recurrence were 12.1% (95% CI, 7.5; 17.7) and 29.4% (95% CI, 21.8; 37.3) for patients treated with standard radiation therapy and 10.4% (95% CI, 4.4; 19.3) and 21.4% (95% CI, 12.6; 31.9) for those treated with intensified radiation therapy. In multivariate analyses, triple-negative subtype and absence of complete pathologic response were associated with a higher risk of loco-regional recurrence. Radiation therapy intensification had no significant impact on locoregional and distant recurrence. For patients with a non-complete pathologic response (n = 172, 71.7%), no significant differences were observed between the 2 groups for loco-regional (P = .80) and distant (P = .39) recurrence. Severe toxicity rates were similar in both groups. CONCLUSIONS: Contrary to other important series, this large retrospective multicentric study did not show a locoregional or distant control benefit of intensified radiation therapy. Pooled prospective studies and meta-analyses of intensified radiation therapy are warranted to endorse this approach.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rogé M, Kirova Y, Lévêque E, et al. Impact of Radiation Therapy Modalities on Loco-regional Control in Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38621608. doi:10.1016/j.ijrobp.2024.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。